Article Text

PDF
Letter
Endothelial cells analysis after intravitreal ranibizumab (Lucentis) in age-related macular degeneration treatment: a pilot study
  1. Consuelo Pérez-Rico1,
  2. Javier Benítez-Herreros1,
  3. Maria Castro-Rebollo1,
  4. Yanira Gómez-SanGil1,
  5. Francisco Germain2,
  6. María Angeles Montes-Mollón1,
  7. Miguel Ángel Teus1
  1. 1Department of Ophthalmology, University Hospital Principe de Asturias, University of Alcalá, Alcalá de Henares, Madrid, Spain
  2. 2Department of Physiology, School of Medicine, University of Alcalá, Alcalá de Henares, Madrid, Spain
  1. Correspondence to Professor Consuelo Pérez-Rico, Department of Ophthalmology, University Hospital Principe de Asturias, University of Alcalá, Carretera Alcalá-Meco s/n. 28805 Alcalá de Henares, Madrid, Spain; cinta.perezrico{at}gmail.com

Statistics from Altmetric.com

Ranibizumab (rhuFabV2, Lucentis; Genentech, San Francisco, California) is a humanised monoclonal antibody fragment, designed to bind all isoforms of human vascular endothelial growth factor-A (VEGF-A) by preventing the interaction of VEGF-A with its receptors VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR).

Although the pharmacokinetic profile of ranibizumab after intravitreal injection in humans has not been determined definitively, ranibizumab has been detected in the aqueous humour after intravitreal standard injections in a rabbit model.1 Moreover, VEGF and its receptors were expressed in the corneal endothelium.2–5 Therefore, ranibizumab in the aqueous humour after intravitreal injections may affect the function of VEGF in the corneal endothelium, being potentially cytotoxic to human corneal endothelial cells. In the present study, we analyse the effect of the …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.